Collegium Ends Grünenthal Nucynta US License for $17 Million Settlement
Collegium Pharmaceutical and Grünenthal settled Nucynta disputes: the US license ends, Collegium pays $17 million and takes over patents, per TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Collegium Pharmaceutical has reached an agreement with Grünenthal that resolves every dispute over Nucynta, including a pending patent case concerning the authorized generic of Nucynta ER, TradingView reports. On October 15, 2026, the two sides mutually terminated the U.S. license dated January 13, 2015, and ended the consent accord dated January 30, 2020, insofar as it covers the defined territory.
Collegium will pay $17 million, after which all royalty duties under the license are considered fully settled, and some Nucynta-related patents move over to the company. Grünenthal has also asked the court to dismiss the lawsuit.
why it matters
For investors, this is mainly the closing of a legal conflict at a small drugmaker. Dropping future royalty payments and concentrating patents at Collegium may simplify management of the Nucynta products, but the $17 million is a one-time payment. The filings contain no revenue figures, so the effect on the company's earnings cannot be gauged from this information.
tags
instruments
sources
- Collegium Pharmaceutical Ends Grünenthal Nucynta U.S. License After $17 Million Settlement — TradingView, 19 October 2026 at 20:13 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗